Site search

Clear filter
2879 results for '' found
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)
/
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
/
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
/
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
/
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
/
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
/
PFOX:  Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
/
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICAC
/
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH
/
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
/
32 33 34 35 36